Related Experiment Video
Updated: Apr 24, 2026

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
Published on: March 26, 2018
Screening for amyloidosis before aortic valve elective replacement: results from the SAVER study
Isabel Mattig1,2,3,4,5, Katrin Wrede-Wihl5,6,7, Selin Sökmen1,2,5
1Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Charitéplatz 1, Berlin 10117, Germany.
Insights
The SAVER study developed a screening tool to detect cardiac amyloidosis (CA) in patients with aortic stenosis (AS). This holistic approach identifies patients at risk, enabling earlier intervention for better outcomes.
Area of Science:
- Cardiology
- Medical Diagnostics
- Genetics
Background:
- Concomitant aortic stenosis (AS) and cardiac amyloidosis (CA) significantly worsen heart failure and reduce life expectancy.
- Early detection of CA in AS patients is crucial for preventing disease progression but remains an unmet clinical need.
Purpose of the Study:
- To establish a simple and effective screening method for cardiac amyloidosis (CA) in patients with aortic stenosis (AS).
- To identify key predictors for CA in AS patients to facilitate early diagnosis and intervention.
Main Methods:
- Prospective cohort study (SAVER) enrolling 1001 AS patients undergoing valve replacement (TAVI/SAVR).
- Initial screening included CA-specific symptoms and history, followed by DPD scintigraphy or MRI for suspected cases.
- Multiple-regression analysis identified predictors for CA risk, including male sex, carpal tunnel syndrome, spinal stenosis, and NT-proBNP.
Main Results:
- 40% of enrolled patients (405/1001) were flagged for potential CA.
- 17 cases (2%) of CA were confirmed through further diagnostics.
- The optimized screening approach achieved an AUC of 0.88, indicating high diagnostic accuracy.
Conclusions:
- The SAVER approach represents the first holistic screening method for CA in AS patients, considering multiorgan manifestations.
- This validated screening tool can be implemented in clinical practice to prevent adverse outcomes associated with combined AS and CA.
Aims:
Concomitant aortic stenosis (AS) and cardiac amyloidosis (CA) result in heart failure and reduced life expectancy. Early detection of CA in AS is an unmet clinical need to prevent disease progression. The SAVER study aims to establish a simple CA screening for AS patients.
Methods And Results:
SAVER is a prospective cohort study enrolling AS patients planned for transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR). Firstly, patients were assessed for CA-specific symptoms and history on top of AS evaluation. Patients with suspected CA underwent DPD scintigraphy or magnetic resonance imaging. Secondly, we performed multiple-regression analysis to identify optimal parameters for selecting patients at risk of CA. From 2021 to 2023, 1001 patients were enrolled, with 405 (40%) flagged for potential CA. Two hundred six (21%) patients received further diagnostics due to the screening and five (0.5%) patients due to physician discretion, leading to 17 (2%) confirmed CA cases. Key predictors of CA included male sex [OR 23.8 (95% CI 2.6; 216.9)], carpal tunnel syndrome [OR 5.5 (95% CI 1.4; 22.0)], spinal stenosis [OR 4.1 (95% CI 1.1; 14.7)], heaviness or numbness of arms or legs [OR 3.8 (95% CI 1.1; 13.3)], NT-proBNP [OR 6.7 (95% CI 1.8; 25.3)], and sparkling myocardium [OR 4.8 (95% CI 1.3; 17.3)]. The optimized approach reached an AUC of 0.88 (95% CI 0.81-0.96).
Conclusion:
The SAVER approach is the first holistic screening method focusing on CA's multiorgan manifestations in AS. This approach can be implemented in clinical settings to prevent futile outcomes of combined disease.
Related Concept Videos
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Aortic Regurgitation III: Medical Management
Aneurysm IV: Nursing Management
Mitral Valve Prolapse II: Assessment and Management
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aneurysm III: Interprofessional Care

